Characterization of Enzymes Involved in Nintedanib Metabolism in Humans.

Drug Metab Dispos

Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences (S.N., R.S., T.F., S.H., Ma.N., Mi.N.) and WPI Nano Life Science Institute (WPI-NanoLSI) (T.F., Ma.N., Mi.N.), Kanazawa University, Kanazawa, Japan; Department of Pharmacokinetics and Nonclinical Safety, Nippon Boehringer Ingelheim C

Published: June 2023


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Nintedanib, which is used to treat idiopathic pulmonary fibrosis and non-small cell lung cancer, is metabolized to a pharmacologically inactive carboxylate derivative, BIBF1202, via hydrolysis and subsequently by glucuronidation to BIBF1202 acyl-glucuronide (BIBF1202-G). Since BIBF1202-G contains an ester bond, it can be hydrolytically cleaved to BIBF1202. In this study, we sought to characterize these metabolic reactions in the human liver and intestine. Nintedanib hydrolysis was detected in human liver microsomes (HLMs) (Clearance [ ]: 102.8 ± 18.9 µL/min per mg protein) but not in small intestinal preparations. CES1 was suggested to be responsible for nintedanib hydrolysis according to experiments using recombinant hydrolases and hydrolase inhibitors as well as proteomic correlation analysis using 25 individual HLM. BIBF1202 glucuronidation in HLM (3.6 ± 0.3 µL/min per mg protein) was higher than that in human intestinal microsomes (1.5 ± 0.06 µL/min per mg protein). UGT1A1 and gastrointestinal UGT1A7, UGT1A8, and UGT1A10 were able to mediate BIBF1202 glucuronidation. The impact of UGT1A1 on glucuronidation was supported by the finding that liver microsomes from subjects homozygous for the allele showed significantly lower activity than those from subjects carrying the wild-type allele. Interestingly, BIBF1202-G was converted to BIBF1202 in HLS9 at 70-fold higher rates than the rates of BIBF1202 glucuronidation. An inhibition study and proteomic correlation analysis suggested that -glucuronidase is responsible for hepatic BIBF1202-G deglucuronidation. In conclusion, the major metabolic reactions of nintedanib in the human liver and intestine were quantitatively and thoroughly elucidated. This information could be helpful to understand the inter- and intraindividual variability in the efficacy of nintedanib. SIGNIFICANCE STATEMENT: To our knowledge, this is the first study to characterize the enzymes responsible for each step of nintedanib metabolism in the human body. This study found that -glucuronidase may contribute to BIBF1202-G deglucuronidation.

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.122.001113DOI Listing

Publication Analysis

Top Keywords

human liver
12
µl/min protein
12
bibf1202 glucuronidation
12
nintedanib metabolism
8
metabolic reactions
8
liver intestine
8
nintedanib hydrolysis
8
liver microsomes
8
proteomic correlation
8
correlation analysis
8

Similar Publications

Objective: To establish organ affiliation of liver microparticles using forensic cytological method based on hepatocytes' morphological characteristics and to determine their species belonging according to the human IgG using a quantitative enzyme-linked immunosorbent assay (ELISA).

Material And Methods: Previously dried microparticles (from 0.2×0.

View Article and Find Full Text PDF

Bifidobacteria are naturally found in the human gut and quickly establish dominance shortly after birth, playing a crucial role in the development and stability of the infant gut microbiota. A growing body of research suggests that host and environmental factors shape the colonization and the relative abundance of bifidobacteria in the infant gut during early life. Understanding the factors that influence bifidobacterial colonization and maintaining normal colonization levels are keys to ensuring gut health.

View Article and Find Full Text PDF

Introduction: Pancreatic adenocarcinomas (PDAC) have a poor prognosis, with a 5-year relative Survival rate of 11.5%. Only 20% of patients are initially eligible for resection, and 50% of patients presented with metastatic disease, currently only candidates' palliative treatment.

View Article and Find Full Text PDF

Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study.

Metab Brain Dis

September 2025

Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu, 1-1 Yanagido, 501-1194, Japan.

Identifying the risk of overt hepatic encephalopathy (OHE) in geriatric patients with cirrhosis remains challenging. This study aimed to investigate the independent factors for OHE development in geriatric cirrhosis and to establish a simple scoring model to identify individuals at risk for OHE. We conducted a retrospective review of geriatric patients with cirrhosis aged ≥ 80 years who were admitted between April 2006 and November 2022.

View Article and Find Full Text PDF

The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).

View Article and Find Full Text PDF